ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT02140125
A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 62
- Registration Number
- NCT02133404
A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 320
- Registration Number
- NCT02038868
An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 86
- Registration Number
- NCT02038673
- Locations
- 🇺🇸
Site US404, Cleveland, Ohio, United States
🇺🇸Site US406, Spartanburg, South Carolina, United States
🇺🇸Site US410, Fairfax, Virginia, United States
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 19
- Registration Number
- NCT01981941
A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01972880
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 234
- Registration Number
- NCT01964170
ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 107
- Registration Number
- NCT01964196
Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01964183
Oral Multiple-dose Study in Patients With Major Depressive Disorder
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01924520
© Copyright 2024. All Rights Reserved by MedPath